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Comparative Overview of Brain Perfusion
Imaging Techniques
Max Wintermark, MD; Musa Sesay, MD; Emmanuel Barbier, PhD; Katalin Borbe´ly, MD, PhD;
William P. Dillon, MD; James D. Eastwood, MD; Thomas C. Glenn, MD; Ce´cile B. Grandin, MD, PhD;
Salvador Pedraza, MD; Jean-Franc¸ois Soustiel, MD; Tadashi Nariai, MD, PhD; Greg Zaharchuk, MD, PhD;
Jean-Marie Caille´, MD; Vincent Dousset, MD; Howard Yonas, MD
Background and Purpose—Numerous imaging techniques have been developed and applied to evaluate brain hemody-
namics. Among these are positron emission tomography, single photon emission computed tomography, Xenon-
enhanced computed tomography, dynamic perfusion computed tomography, MRI dynamic susceptibility contrast,
arterial spin labeling, and Doppler ultrasound. These techniques give similar information about brain hemodynamics in
the form of parameters such as cerebral blood flow or cerebral blood volume. All of them are used to characterize the
same types of pathological conditions. However, each technique has its own advantages and drawbacks.
Summary of Review—This article addresses the main imaging techniques dedicated to brain hemodynamics. It represents
a comparative overview established by consensus among specialists of the various techniques.
Conclusions—For clinicians, this article should offer a clearer picture of the pros and cons of currently available brain
perfusion imaging techniques and assist them in choosing the proper method for every specific clinical setting. (Stroke.
2005;36:e83-e99.)
Key Words: computed tomography  magnetic resonance imaging  tomography, emission computed
 ultrasonography, Doppler, transcranial  perfusion  stroke  tomography, emission-computed, single-photon
Numerous imaging techniques have been developed and ap-plied to evaluate brain hemodynamics. The main imaging
techniques dedicated to brain hemodynamics are positron emission
tomography (PET), single photon emission computed tomography
(SPECT), Xenon-enhanced computed tomography (XeCT), dy-
namic perfusion computed tomography (PCT), MRI dynamic
susceptibility contrast (DSC), arterial spin labeling (ASL), and
Doppler ultrasound. Most of these techniques rely on mathematical
models developed at the beginning of the century.1–4 All these
techniques give similar information about brain hemodynamics in
the form of parameters such as cerebral blood flow (CBF) or
cerebral blood volume (CBV). They use different tracers (diffusible
or nondiffusible, endogenous or exogenous) and have different
technical requirements. Some are feasible at bedside and others not.
The duration of data acquisition and processing varies from one
technique to the other. Brain perfusion imaging techniques also
differ by quantitative accuracy, brain coverage, and spatial resolu-
tion (Table 1). These differences constitute as many advantages as
drawbacks in various clinical settings.
The goal of this article is a comparative overview of the main
brain hemodynamics imaging techniques established by consen-
sus among specialists of the different techniques. For clinicians,
this should offer a clearer picture of the pros and cons of
available brain hemodynamics imaging methods and assist them
in choosing the proper technique for every specific clinical
setting. The different imaging techniques are presented accord-
ing to the same template. A technical description, including what
kind of contrast is used and whether radiation is involved, is
followed by a discussion of the technical requirements. Notably,
the duration of a routine study is addressed. Then comes an
in-depth discussion of the interpretation of the results, including
a description of the underlying mathematical model, the duration
of the data postprocessing, the measured parameters, the accu-
racy of the values in normal parenchymal pixels, in pixels
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containing larges vessels, and in pathological pixels with altered
hemodynamics, and the reproducibility of the technique. The
feasibility of the technique in children and at bedside is also
addressed, as well as the afforded brain coverage and spatial
resolution and the minimal time interval between 2 successive
studies. Finally, the typical clinical applications are reported, as
well as the availability of the technique in the emergency setting.
Positron Emission Tomography
Tadashi Nariai, MD, PhD;
Katalin Borbe´ly, MD, PhD
Technical Description
PET is a noninvasive diagnostic tool that provides tomo-
graphic images of quantitative parameters describing various
aspects of brain hemodynamics, including regional CBF
(rCBF), regional CBV (rCBV), regional oxygen extraction
fraction (rOEF), and cell viability, but also proliferation or
metabolic activity of tissues, regional cerebral metabolic rate
of oxygen (rCMRO2) or glucose, and neurotransmission
processes, etc. These images result from the use of different
substances of biological interest labeled with positron emit-
ting radioisotopes (PET radiopharmaceuticals).
The PET tracers used for the measurement of CBF are 15O2,
C15O2, and H215O. H215O is administered directly by intrave-
nous injection; a 1- to 2-minute scan is performed and its
results combined with an arterial blood sampling measure-
ment serving as an input function, and application of the
Kety–Schmidt model to this data set leads to quantitative
CBF maps.5,6 C15O2 is inhaled continuously for 8 to 10
minutes, the catalytic action of carbonic anhydrase in the
pulmonary vasculature resulting in rapid transfer of the 15O
label to H215O. A 1- to 2-minute scan is performed once a
TABLE 1. Overview of the Imaging Techniques Dedicated to Brain Hemodynamics
Brain Perfusion Imaging Techniques
PET SPECT XeCT PCT DSC ASL Doppler
Feasibility
Age range Adults (and children for
static exams)
Adults (and children) Adults (and children) Adults (and children) Adults (and children) Adultschildren Adultschildren
Bedside No In some instances No No No No Yes
Contrast material 15O2, C15O2, H215O 133Xe, 99mTc-HMPAO, 99mTc-ECD,
123I-IMP (diffusible)
Stable xenon gas
(diffusible)
Iodinated contrast
material (nondiffusible)
gadolinium chelate
(nondiffusible)
None (endogenous contrast) None (endogenous
contrast)
Radiation/study 0.5–2 mSv 3.5–12 mSv 3.5–10 mSv 2–3 mSv None None None
Data acquisition 5–9 min 10–15 min 10 min 40 sec 1 min 5–10 min 10–20 min
Data processing 5–10 min 5 min 10 min 5 min 5 min 5 min None
Interpretation
Mathematical model Kety–Schmidt model Principle of chemical
microspheres for 99mTc tracers,
Kety–Schmidt model
for 133Xe and 123I-IMP
Kety–Schmidt model Meier–Zierler model Meier–Zierler model Meier–Zierler model Other
Assessed
parameters
CBV, CBF, rOEF, glucose
metabolism
CBF CBF CBF, CBV, MTT, TTP,
permeability map
CBF, CBV, MTT, TTP,
permeability map
CBF ICA BFV
Large vessels* No influence on results No influence on results No influence on results Influence results Influence results No influence on results Not applicable
Quantitative
accuracy
Yes Yes for 133Xe and 123I-IMP; no
for the others tracers
Yes Yes Not in daily practice Yes Yes for hemispheric CBF
Including for low
perfused areas†
Yes Not applicable Yes Yes Not applicable Not 10 mL/min/100 g Not applicable
Reproducibility 5% 10% 12% 10–15% 10–15% 10% 5%
Brain coverage Whole brain Whole brain 6-cm thickness 4–5 cm thickness Whole brain Whole brain One measurement for
each hemisphere
Spatial resolution 4–6 mm 4–6 mm 4 mm 1–2 mm 2 mm 2 mm Not applicable
Minimal time
interval between 2
successive exams
10 min 10 min (split-dose technique
for 99mTc-HMPAO, 99mTc-ECD
and 123I-IMP)
20 min 10 min 25 min 0 min 0 min
Clinical applications
Clinical fields Chronic cerebrovascular
disorders
(Acute and) chronic
cerebrovascular disorders
Acute and chronic
cerebrovascular disorders
Acute and chronic
cerebrovascular disorders
Acute and chronic
cerebrovascular disorders
Chronic cerebrovascular
disorders
Acute cerebrovascular
disorders
Trauma Trauma Trauma Trauma Trauma
Dementia and psychiatric
diseases
Dementia and psychiatric
diseases
Vasospasm Vasospasm Vasospasm Neurodegenerative
disorders
Vasospasm
Epilepsy Epilepsy Epilepsy
Brain tumors Brain tumors Brain tumors Brain tumors
Brain activation studies Brain activation studies Brain activation studies
Emergency setting No In some instances Yes Yes Yes Yes Yes
*“Influence of large vessels” is meant to report for which imaging techniques the CBF values in pixels containing large vessels are significantly superior to the
capillary CBF values that are of interest.
†“Quantitative accuracy in low perfusion areas” is meant to report which imaging techniques are quantitatively accurate even in case of altered hemodynamics
areas, for example, in ischemic areas.
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steady state is reached; the same approach as that described
above is used to calculate a quantitative CBF map.7
Successive inhalation of 15O2, C15O2, and C15O over 60
minutes allows measurement of the rCBV, the rCMRO2, as
well as the rOEF, which designates the fraction of the oxygen
delivered to brain (40%3 is extracted by the brain paren-
chyma and metabolized8–10).
18F fluorodeoxyglucose PET can measure the regional
glucose consumption of the living tissues and is now widely
used for the evaluation of cancer with whole body scanning.
Additionally, it is a reliable method to detect a regional
metabolic deficit in the brain.11,12
PET radiopharmaceuticals are cyclotron products and have
a very short half-life (18F 1.7 hours; 15O 2 minutes; 13N 10
minutes; 11C 20 minutes). Whole body radiation exposure by
PET examination is usually 0.5 to 2.0 mSv per scan. The
radiation dose may differ among institutions depending on
the protocol or quality of the PET camera. The duration of the
data acquisition depends on the selected method and tracer. It
typically ranges 5 to 9 minutes for a routine clinical study.
Technical Requirements
In addition to the access to cyclotron PET radiopharmaceu-
ticals, PET imaging requires a PET camera or scanner,
usually consisting of several full-ring detectors: BGO (bis-
muth germanate orthosilicate), lutetium orthosilicate, or gad-
olinium orthosilicate. Variations on this basic design include
partial-ring BGO–dedicated PET scanner and dedicated PET
scanner with 6 position-sensitive sodium iodide detectors. A
hybrid PET–computed tomography (CT) gives the opportu-
nity for accurate registration and exact correlation of PET
functional aspects with anatomical findings. These cameras
are much faster (4) than the older generation of PET
cameras.
Interpretation
As described above, PET measurements of CBF are mainly
performed using the bolus injection of H215O or by the
continuous inhalation of C15O2. In both methods, CBF can be
quantified based on Kety–Schmidt equation.10 PET results
consist in maps describing CBF, CBV (CBV is calculated
from the ratio of the radioactivity in brain to that in peripheral
whole blood), rOEF, and rCMRO2 values. Data processing to
obtain these maps typically takes 5 to 10 minutes. PET results
can be visually interpreted on a computer screen. Correlation
with structural information (CT, MRI) is highly desirable for
accurate interpretation.13 Quantification advantageously com-
pletes the visual interpretation and allows to objectively
assess changes in postintervention or follow-up studies. The
main advantage of PET technique lies in this quantitative
accuracy, even in pixels containing large vessels and in brain
regions with altered brain perfusion or metabolism. PET
results are very reproducible in the current standardized
settings.10,14,15
Feasibility
PET imaging is feasible in children but is not available at
bedside. PET technique affords whole brain coverage. The
spatial resolution of PET studies ranges from 4 to 6 mm.
The minimal time interval between 2 successive examina-
tions is 10 minutes for 15O-labeled compound.
Clinical Applications
Because it is not possible in the emergency settings, PET is
used mainly in chronic clinical conditions. Chronic cerebro-
vascular disorders (Figure 1) are the most frequent applica-
tion of CBF and rOEF measurements. In patients with chronic
internal carotid artery (ICA) occlusion, elevated rOEF values
are now considered a major key indicator for predicting
future impending infarction and determining the indication
for bypass surgery.16–18 Other PET applications are on brain
tumors and epilepsy (Figure 2) as well as, to a lesser extent,
dementia, movement disorders, and brain activation studies
Figure 1. PET CBF and OEF images in a
40-year-old female with moyamoya dis-
ease examined before (Pre) and after
(Post) a right-side bypass surgery.
Before treatment, CBF and OEF are
decreased and increased, respectively, in
the right frontal region (white arrows),
hallmarking poor CVR. CBF and OEF
were significantly improved by bypass
surgery (yellow arrows).
Figure 2. A 42-year-old female with frontal lobe epilepsy. Sub-
traction of interictal from ictal 99mTc-ECD SPECT images and
coregistration with the patient’s MRI identify the epileptic focus
more conspicuously than 18F fluorodeoxyglucose (FDG) PET
images.
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(functional mapping studies).19 PET may be used for research
purposes to validate other brain perfusion methods.20
Single Photon Emission CT
Tadashi Nariai, MD, PhD;
Katalin Borbe´ly, MD, PhD
Technical Description
SPECT is a noninvasive technique generating tomographic
images of the 3D distribution of a specific radiopharmaceu-
tical, which, depending on its nature, may reflect regional
cerebral hemodynamics, dopamine, or other transporter dis-
tribution, etc.21
133Xenon (133Xe) is historically the most important method
for measuring brain hemodynamics.22 However, the gamma
rays emitted by 133Xe are of low energy, resulting in abundant
scatter and limited spatial resolution. Consequently, retention
tracers such as [99mTc]hexamethylpropylenamine oxime
(99mTc-HMPAO), 99mTc-Bicisate (ethyl cysteine dimer
[ECD]), and 123I inosine–5-monophosphate (123I-IMP) are
more commonly used in clinical SPECT imaging of brain
hemodynamics. The doses used in adults are typically 20
milliCuries (mCi) for HMPAO, 30 mCi for ECD, and 5 mCi
for 123I-IMP. These activities represent effective doses of
6.88, 12.21, and 3.53 mSv, respectively.
Using retention tracers, the total scan time for a SPECT
examination is 10 to 15 minutes, depending on the imaging
device. The goal is to achieve a total of 5 million counts.
Compared with step and shoot technique, the continuous
acquisition mode may shorten the total scan time and reduce
the mechanical wear of the system. Segmentation of the data
acquisition into multiple sequential acquisitions allows exclu-
sion of bad data (eg, removing segments of projection data
with motion artifacts).
Technical Requirements
Multiple-detector (3- or 4-headed) or other dedicated SPECT
cameras for brain imaging should be used for the data
acquisition because they afford superior results compared
with single- or 2-headed cameras. Use of high-resolution
collimation is recommended. The detector pan and zoom
capabilities are often used to ensure that the entire brain is
included in the field of view while allowing the detector to
clear the patient’s shoulders.23
Reconstruction of 2D images from the projection data
collected by the SPECT cameras is usually performed by
filtered back projection (FBP). In addition to FBP, different
algorithms have been developed to correct for photon atten-
uation, a possible source of image distortion. The most recent
correction techniques are based on measured attenuation
maps using transmission scans to reveal an attenuation map
specific to each patient. Scattering of the photons in the body
of a patient is another important source of error in quantifi-
cation of activity distribution. The amount of scatter can vary
between 10% and 60% of the detected events. Different
techniques, such as pulse height analysis, use of multiple
energy windows, or deconvolution, allow subtraction of the
scatter from the projection data before the image reconstruc-
tion. Finally, several iterative reconstruction methods such as
ordered subsets expectation maximization have been pro-
posed recently to correct images for artifacts and noise.
Starting from an “initial guessed counts distribution” in the
voxel grid or from an already created FBP image, the ordered
subsets expectation maximization algorithm elaborates itera-
tively the image grid, the final end point being to reach a state
in which each pixel contains the number of counts it was
containing in the raw matrix.23,24
Interpretation
Data processing relies on the microsphere principle for the
Tc-99m tracers and on the Kety–Schmidt model for the 133Xe
and 123I-IMP, leading to the calculation of rCBF maps. Data
processing typically takes 5 minutes.
The rCBF maps obtained with SPECT can be statistically
evaluated compared with the normal control to depict the
regions with abnormal perfusion. If SPECT results are fairly
reproducible (10% of variability), they are not quantitative in
the current standardized settings. Particularly, the uptake of
99mTc-HMPAO is not linearly related to CBF, requiring
special correction.25 An exception is 133Xe SPECT technique,
which uses a single detector positioned over the right lung to
measure an arterial input function (AIF) and to calculate
quantitative CBF values.
Feasibility
SPECT technique can be used at bedside and is feasible in
children. One specific bedside indication for SPECT is
seizure. Because SPECT uses a retention tracer for measure-
ment of cerebral perfusion, the radiopharmaceutical can be
administered at the moment of the seizure and imaging
performed later, after stabilization of the patient, to identify
the active epileptic focus.
SPECT affords whole brain coverage. The typical spatial
resolution of SPECT studies is 4 to 6 mm. In case of
challenges (acetazolamide), 133Xe SPECT examinations can
be repeated, and the split-dose technique can be used for
99mTc-HMPAO, 99mTc-ECD, and 123I-IMP, with administration
of 2 half doses 1 hour apart from each other. The obtained
images are subtracted from each other.
Clinical Applications
The main indications for SPECT studies are acute and
chronic cerebrovascular diseases and presurgical localization
of epileptic foci.
Perfusion SPECT provides valuable information in acute
stroke with respect to complications,26 outcome,27,28 or choice
of treatment strategy.29 In chronic cerebrovascular disease,
SPECT assessment of functional reserve capacity may guide
decisions regarding vascular surgery.30,31
Ictal SPECT studies (eventually complemented by interic-
tal investigations) are indicated in focal epilepsy for the
localization of the epileptic focus before epileptic surgery32
(Figure 2).
SPECT has also been reported to show abnormalities in
head trauma patients33,34 and in a variety of psychiatric
disorders (such as major depression, post-traumatic stress
disorder, and schizophrenia) and to afford early detection and
differential diagnosis of dementia.35,36 Perfusion SPECT may
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provide helpful information in viral encephalitis (eg, herpes
simplex encephalitis), vasculitis, and HIV encephalopa-
thy.37,38 Finally, SPECT assessment of arrest of cerebral
perfusion is an accurate technique to confirm brain death.39
Xenon-Enhanced CT
Musa Sesay, MD;
Howard Yonas, MD
Technical Description
XeCT has been used for 20 years to evaluate quantitative
CBF in humans.40 Stable (nonradioactive) Xenon is inhaled
and serves as contrast material. The Xenon gas rapidly
dissolves in blood, freely crosses the lipid-rich blood–brain
barrier, and enters the brain. CBF is calculated by using the
modified Kety–Schmidt equation, which integrates the fol-
lowing parameters: the time course of the concentration of
Xenon in the blood and brain, and the blood–brain partition
coefficient (or lambda) for Xenon.41 The concentration of
Xenon in the brain is measured directly by the CT scanner.
The concentration of Xenon in arterial blood is determined
indirectly and accurately from the end-tidal Xenon provided
that the pulmonary function is not severely impaired.42 The
current technique requires the inhalation of a mixture of
Xenon (28%) and oxygen (21% to 60% as clinically indi-
cated) within a data acquisition period of 4.3 minutes.43 After
the acquisition of a baseline scan of the entire head, 4 to 6
contiguous 10-mm-thick levels are selected for CBF mea-
surement. Each level is scanned 6 during the inhalation
period, with exact table relocation. At the end of inhalation,
Xenon is rapidly washed out from cerebral tissues (half-life
40 seconds).
Adverse reactions to stable Xenon-like nausea, reversible
alteration of sensorium, or respiratory depression have been
reported in 0.1% of cases.44 In addition, patient motion is a
serious limitation to the technique. It can produce artifacts,
making interpretation difficult and inaccurate. Head immobi-
lization devices, sedation in some patients, and lowering the
Xenon concentration to 28% has lessened the incidence of
motion artifacts.43 Patients with severe respiratory disease,
patients with full stomach, ventilated patients with a tidal
volume 250 mL, and restless patients who cannot be
adequately sedated should be excluded from XeCT studies.
The average radiation dose to the brain from a typical study
in an adult ranges from 3.5 to 10 mSv.45
Technical Requirements
XeCT technology requires a CT scanner and a Xenon
delivery system (ENHANCER, DDP; or XETRON, ANZAI).
The latter is a compact and fully mobile unit that can be
moved between CT suites. It houses the disposable Xenon gas
cylinders. A wall outlet source or an oxygen tank can be used
for oxygen delivery. The machine is equipped with continu-
ous monitors of CO2, O2, and Xenon integrated within a
low-resistance respiratory circuit that is initially open to room
air, then partially open and finally closed on using. The later
feature is vital for limiting the use of Xenon to 5 L per
study. The monitors not only provide a means of maintaining
inhaled Xenon and O2 within 1% of prescribed concentration
but also function as a monitor of apnea. Studies are easily
accomplished with a mask or via connection to an endotra-
cheal tube with the patient’s volume ventilator being used to
maintain ventilation through the enhancer.43
The medical-grade Xenon is available and distributed
worldwide. However, in the United States, Xenon is not
currently approved by the Food and Drug Administration
(FDA). The technology is only available at this time under
IND (investigational new drug) status.
Interpretation
As mentioned above, XeCT technique relies on the Kety–
Schmidt equation to extract from the acquired data quantita-
tive information about CBF and the partition coefficient
lambda between blood and tissue.46 Superimposition of the
numerical data on the anatomic image yields a high-
resolution (full-width half maximum 4 mm) map of quan-
titative flow data that is tightly coupled to cerebral anatomy.47
With the addition of a gray or color scale, the data are
converted to a map for visual inspection on which regions of
interest (ROIs) can be drawn for rCBF quantitative assess-
ment within a wide spectrum of CBF values (0 to 140 mL/100
g per minute). A confidence map is also produced to
demonstrate the effects of any patient motion and other
artifacts on the data. The data processing requires 10
minutes.
Although the stability of the flow value in a single voxel of
10 mm3 is poor, the reliability of the data from an ROI of
100 voxels is 12%. This reliability, despite the pharma-
cological property of Xenon to directly increase CBF by 20%
to 30%, is explained by the fact that nearly all the important
flow data are acquired before this flow activation (the latter
becomes significant only after 2.5 minutes of inhalation).48
Reliability is also increased by use of a flow phantom that
permits standardization of the data and the calibration of
scanners from different manufacturers.
Feasibility
Because of this radiation risk, XeCT in children is only
recommended after careful consideration of the potential
risks and benefits. XeCT does not afford whole brain cover-
age, but still, 4 to 6 contiguous 10-mm-thick slices can be
evaluated. The minimal time interval between 2 successive
examinations is 10 minutes. XeCT challenge studies, for
example for measuring the vasodilatory response to acetazol-
amide, can thus be performed in an outpatient setting within
30 minutes43 (Figure 3).
Clinical Applications
Cerebrovascular disorders are the main clinical application of
XeCT, which has the ability to provide measurements of
equal validity within the cortex as well as the depth of the
brain that can determine proximity to the ischemic thresh-
old.49 Large clinical series of balloon test occlusion have
demonstrated the ability of XeCT to select the patients who
require bypass surgery before vascular sacrifice.50 XeCT has
also been shown to be useful in understanding the heteroge-
neity of flow alterations after closed head injury, providing
Wintermark et al Brain Perfusion Imaging Techniques e87
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important insights into the efficacy of therapies designed to
improve CBF.51
As mentioned above, the short half-life of inhaled Xenon
makes XeCT CBF particularly adequate for repeat (chal-
lenge) tests to study cerebrovascular physiology (Figure 3).
Cerebrovascular reserve assessed by examining the quantita-
tive response of flow in patients with occlusive vascular
disease has provided a means for identifying high-risk sub-
groups.52 The efficacy of blood pressure elevation has been
monitored in patients with vasospasm following postsub-
arachnoid hemorrhage.53 For patients with elevated intracra-
nial pressure after closed head injury, the ability to monitor
the local, regional, and global effects of PCO2 lowering has
provided specific data as to the safety and efficacy of CO2
manipulation.54
Dynamic PCT
James D. Eastwood, MD;
William P. Dillon, MD;
Max Wintermark, MD
Technical Description
Dynamic PCT is a technique for measuring brain hemody-
namics that uses first-pass tracer methodology after bolus
infusion of intravenous iodinated contrast material. Typically,
continuous cine scanning is performed during a total scanning
time of 40 to 45 seconds, with a scan rate of 1 image per
second. The bolus, typically 40 to 50 cc of 300 to 370 mg/dL
iodinated contrast material, is administered via an arm vein.55
Although one would expect a higher radiation dose with
PCT than standard unenhanced CT, it is necessary to recall
that low milliamperes (100 to 150 mA) or kilovolt protocols
(80 to 90 kilovolt peaks) are typically used for PCT studies to
limit dose. The effective radiation dose involved in a PCT
series ranges 1.6 to 2.0 mSv (versus 2.5 mSv for a standard
unenhanced CT of the brain).56 Iodinated contrast is safe as
long as not used in patients with renal failure or diabetes
mellitus.57
Technical Requirements
For adequate PCT data acquisition, a helical CT scanner
capable of operating in the cine mode is needed. Multislice
CT scanners offer the advantage of greater tissue coverage
per acquisition (usually 2 cm) compared with single-slice CT
scanners (typically 1 cm). In case of a protocol using 2
successive bolus administrations, a total coverage of 4 to 5
cm can be achieved.55
An automatic injector of contrast material capable of at
least 3 to 4 cc/second infusion rates is also necessary for an
adequate PCT examination to obtain a short bolus. Such an
injection rate requires a peripheral venous access with a
catheter size of 22 gauge (20 or 18 gauge may be
optimal).58
Interpretation
PCT data processing that can typically be achieved in 5
minutes is performed with postprocessing software using
either rate-of-upslope estimation of CBF (for infusion rates
above 6cc/second) or deconvolution analysis (for infusion
rates of 4 to 5 cc/second). Only deconvolution analysis leads
to quantitatively accurate results, including in areas with low
perfusion.59 However, PCT technique overestimates brain
hemodynamics values in pixels including large vessels.60
Ideally, images of CBF, CBV, and mean transit time
(MTT) are interpreted together on a workstation permitting
the use of visual assessment combined with quantitative
analysis with ROIs. Regions of decreased hemodynamics are
often represented as regions of prolonged MTT. MTT maps
have the property of generally being quite sensitive to the
presence of altered brain hemodynamics. Comparing CBF,
CBV, and MTT values between abnormal regions and mirror-
image control regions is an effective method of measuring the
Figure 3. A 40-year-old patient pres-
enting with posture-induced ischemic
events ipsilateral to a right carotid occlu-
sion. Comparison of preacetazolamide
and postacetazolamide XeCT images
demonstrates an increase in rCBF values
in the healthy hemisphere only. Subtrac-
tion image confirms the existence of a
stealing effect with poor CVR predomi-
nantly in the left middle cerebral artery
territory.
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degree of underperfusion present in a given case or location.
Generally, CBF values can be interpreted using thresholds
established using other methods, notably XeCT.61,62 Another
way to proceed is to apply the concept autoregulation and to
evaluate simultaneously MTT and CBV maps. Within areas
with prolonged MTT, the regions with increased CBV result-
ing from vasodilatation and collateral recruitment are consid-
ered to have preserved autoregulation and to represent “tissue
at risk,” whereas regions with decreased CBV correspond to
the infarct core63,64 (Figure 4).
Feasibility
It is presently not possible to perform a PCT examination at
the bedside. The patient must be transported to the CT
department.55
PCT has a limited spatial coverage (20- to 48-mm thick-
ness). However, the issue of spatial coverage will be ad-
dressed in the near future through the development of
multislice CT scanners with greater arrays of elements. Even
presently, PCT has demonstrated 95% accuracy in the delin-
eation of the extent of supratentorial strokes despite its
limited spatial coverage.65
The minimal time interval between 2 successive PCT
series is 3 to 6 minutes, allowing performance of 2 successive
PCT series in the same study to increase spatial coverage and
to combine PCT imaging with vasodilatory challenge (eg,
acetazolamide challenge).66
Clinical Applications
PCT can rapidly detect the size of hypoperfused regions in
the setting of acute stroke.61–64 At the time of this writing,
definitions of infarct core and penumbra are undergoing
active research to provide understanding of how the method
could potentially be used to guide therapy. Anecdotally, in
the setting of unilateral carotid occlusion, PCT imaging may
be combined with vasodilatory challenge (eg, acetazolamide
challenge) to permit identification of tissue at risk for future
infarction. Baseline imaging may reveal increased MTT,
increased CBV (because of vasodilatation), and decreased
CBF. After acetazolamide infusion, further decrease in CBF
Figure 4. A 55-year-old male patient
admitted for right homonymous hemi-
anopsia and right-body sensory loss.
The admission noncontrast CT (NCT),
obtained 6 hours after symptom onset,
was considered unremarkable, except for
a dense left posterior cerebral artery
(PCA; arrowheads). PCT demonstrates
prolonged MTT and reduced rCBF val-
ues in the left PCA territory. However,
rCBV values are reduced only in a small
part of the left thalamus but increased in
the rest of the PCA territory. These areas
correspond to infarct and penumbra,
shown in red and green, respectively.
The admission CT angiogram (CTA)
demonstrates an occluded left P1 seg-
ment that is recanalized but remains
focally stenotic on the follow-up MRA
obtained 3 days later. The follow-up DWI
examination demonstrates a completed
stroke in the predicted infarct core in the
left thalamus. The penumbra as depicted
on the admission PCT did not infarct,
most likely as a result of early
recanalization.
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is observed in tissue at risk for ischemia without interven-
tion.66 PCT may be helpful for observing the effects of focal
vasospasm after subarachnoid hemorrhage.67,68
Finally, PCT can also be used in head trauma patients as a
prognostic factor69 as well as to guide management of
intracranial pressure in these patients.70
The wide availability of CT scanners in the emergency
departments (EDs) and the short duration of PCT examina-
tions make PCT an ideal technique for ED patients, including
stroke patients and head trauma patients.69–71
Dynamic Susceptibility–Weighted
Bolus-Tracking MRI
Ce´cile B. Grandin, MD, PhD;
Salvador Pedraza, MD
Technical Description
DSC relies on the measurement of the T2 or T2* decrease
during the first pass of an exogenous endovascular tracer
through the capillary bed.72,73 The technique requires ultrafast
imaging, such as echo planar imaging, and principles of echo
shifting with a train of observations or spiral imaging.
Gradient echo (GRE) or spin echo (SE) sequences can be
used, but the signal change measured with GRE (T2*) is
greater than that measured with SE (T2), allowing one to
use a shorter echo time and a lesser amount of contrast agent.
The sequence duration is 1 minute, and the sampling rate
(repetition time of the sequence) should be kept 2 seconds.
This can be achieved with GRE sequences for whole brain
coverage (up to 24 slices).74 The used tracer is a conventional
chelate of gadolinium, injected through an 18-G catheter into
a peripheral vein at a regular dose of 0.1 mmol/kg for GRE or
0.2 mmol/kg for SE, and at an injection rate of 5 to 10
mL/second, immediately followed by a 20- to 30-mL saline
flush.72
DSC does not expose patients to ionizing radiation. Intol-
erance to gadolinium chelates is very rare. The contraindica-
tions are those of MRI in general: pacemakers and some other
implanted metallic or electronic devices or obesity (150
kg). Fixed ferromagnetic dental devices and intracranial clips
generate prominent artifacts. Claustrophobia or agitation may
require sedation.
Technical Requirements
Most 1.5-T magnetic resonance (MR) scanners are now
equipped with the fast-imaging capabilities required for DSC.
The use of a power injector is recommended.
Interpretation
DSC relies on the application of the indicator dilution theory.4
In case of blood–brain barrier rupture, the indicator dilution
theory must be modified, and a measure of the permeability
must be introduced.75,76 For qualitative hemodynamic mea-
surements, a preload dose of contrast before the bolus is an
easier way to minimize the effect of contrast leakage.
Using commercially available software, various parameters
can be calculated in a few minutes from the time-intensity
curves measured in each pixel, allowing one to reconstruct
parametric maps. The most commonly calculated parameters
are: time to peak (TTP); apparent MTT, corresponding to the
first moment of the curves; CBV calculated from the area
under the curve; and CBF index, equal to CBV/apparent
MTT. These maps do not afford quantitative assessment of
brain hemodynamics but provide indicators of hemodynamic
disturbances that are very useful in a clinical setting. They
can be interpreted visually or semiquantitatively by calculat-
ing the ratio or difference between the values in an ROI
placed in the abnormal area and a mirror ROI placed in the
contralateral area considered as a normal reference. Note that
for the moment, there is no standardization in the interpreta-
tion of the DSC parametric maps.77
The quantification of CBF by DSC requires the deconvo-
lution of the measured tissue curves by an AIF.78,79 If the AIF
is adequately calibrated, absolute quantitative CBV and CBF
maps can be obtained.80 This step is more complex with DSC
than with PCT because the relationship between the signal
intensity and the gadolinium concentration is not always
linear.81 Several studies have demonstrated a good correlation
between the absolute CBV and CBF values obtained accord-
ing to this approach compared with PET or XeCT.82–84 Note
that to interpret the DSC perfusion maps quantitatively or
semiquantitatively, it is necessary to mask out the large
vessels (very prominent with GRE sequences). Low perfusion
values can be accurately measured until 8 mL/minute per
100 g. Under this level, the signal-to-noise ratio becomes too
low for a precise quantification.85 The reproducibility of the
method ranges 10% to 15%.86
Feasibility
DSC has no age limitation and can be performed on children.
MRI is not a bedside technique. It is not available at night and
during weekends in many institutions.
A spatial resolution 1.51.54 mm is routinely avail-
able, but the actual in-plane resolution is usually closer to
2 mm, considering the degradation of the point-spread func-
tion during the bolus passage.73
A delay of 25 minutes between successive contrast injec-
tions has been shown to be sufficient for repeated CBF
measurements, allowing one to assess the CVR. This delay
may be longer for successive CBV measurements.86,87
Clinical Applications
The main clinical applications of DSC are acute stroke,
chronic cerebrovascular disease, and tumors.
MRI can be performed in the emergency setting of hyper-
acute stroke. DSC is used in association with diffusion-
weighted imaging (DWI) and MR angiography (MRA) for
the early evaluation of stroke patients. Prolonged TTP and
MTT values are the most sensitive features to detect a
hemodynamic disturbance. CBV and CBF maps are more
difficult to visually interpret (especially in white matter) but
better reflect brain perfusion.88–90 A threshold can be applied
to DSC maps to identify the area at risk for infarction and
predict outcome, but no consensus has been achieved regard-
ing the specific thresholds that might distinguish reversible
and irreversible ischemia.91,92 The presence of a mismatch
(DSC abnormality larger than the diffusion abnormality),
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vessel occlusion on MRA, and absence of hemorrhage should
prompt thrombolytic treatment93–95 (Figure 5). DSC has also
been used successfully to assess the cerebrovascular re-
serve85,96 and vasospasm.97
In the management of patients with brain tumors, DSC can
be combined with fine anatomic imaging, DWI, and spec-
troscopy, providing the most comprehensive information in
one examination and leading to a high benefit/cost ratio.98,99
DSC can differentiate high-grade glial tumors with neovas-
cular proliferation and high CBV values with respect to
low-grade glial tumors with low CBV. DSC can also evaluate
the response to treatment (CBV decrease), differentiate tumor
recurrence (high CBV) from radiation necrosis (low CBV),
and distinguish tumor (high CBV) from infection (low CBV,
but depending on the etiology) or tumefactive multiple
sclerosis lesions (low CBV).100–102
Arterial Spin Labeling
Emmanuel Barbier, PhD;
Greg Zaharchuk, MD, PhD
Technical Description
ASL, also referred to as arterial spin tagging, relies on the
detection of magnetically labeled water. Once the magneti-
zation of the inflowing water has been modified (generally
inverted) upstream, it induces a small MR signal change
downstream (a few percent of the tissue magnetization).
Meanwhile, the magnetization of the perfusion tracer (ie, the
labeled water) is rapidly relaxing: the return of the longitu-
dinal magnetization toward its equilibrium values takes a few
seconds in the best cases (time constant T1).103,104
Numerous ways to do the spin labeling have been de-
scribed.105–107 The existing techniques can be sorted out in 2
Figure 5. A 64-year-old male patient
admitted with aphasia and right-body
motor deficit. Admission MRA shows a
proximal stenosis of the left middle cere-
bral artery (MCA; arrow). DWI and appar-
ent diffusion coefficient (ADC) maps fea-
ture a focus of restricted diffusion in the
deep territory of MCA (arrowheads), con-
sistent with acute stroke. TTP and MTT
maps demonstrate an extensive alter-
ation of brain hemodynamics. The DWI–
perfusion-weighted imaging mismatch is
classically considered as a hallmark of
tissue at risk or penumbra.
Figure 6. Principle of ASL MRI perfusion
imaging. For demonstration, the continu-
ous labeling method is depicted. Two
sets of images are acquired: one (on the
left) in which water protons are inverted
proximally to the imaged slice and one
(on the right) in which they are not. Sub-
traction of these 2 images provides a
map of the distribution of the labeled
water, which may be converted into
quantitative CBF. Because the difference
between the “label” and “control” images
is on the order of 1% of the baseline
images, multiple image pairs are col-
lected and their signals summed to
achieve adequate signal-to-noise. A typi-
cal ASL image at 1.5 T requires 5 to 10
minutes to acquire.
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categories: pulsed techniques and continuous techniques,
depending on how the spin labeling is performed. In both
cases, a certain amount of blood magnetization is labeled
before it irrigates the tissue of interest. With a “pulsed
labeling” technique, the labeling is obtained by inverting the
blood water magnetization in a thick slab of tissue located
next to the slices of interest using a short (a few milliseconds)
shaped radio frequency (RF) pulse. To better define the tail of
this inverted blood bolus, a saturation pulse can be used
advantageously.108 With a “continuous labeling” technique
(Figure 6), the labeling is performed continuously (during a
few seconds) at the level of a plane through which blood
flows (for the brain, this plane is located at the carotid level)
either with the same coil or with a separate RF coil.109
Finally, a recent approach has been proposed for which the
blood magnetization is selectively inverted based on the
blood velocity. This new pulsed technique differs from the
classical pulse inversion and opens a new range of
possibilities.110,111
The different ASL techniques share one characteristic: no
contrast media is needed. ASL uses endogenous water as a
tracer. A typical acquisition lasts between 5 and 10 minutes
depending on the scanner quality (magnetic field, RF coil
sensitivity, etc). Multiple pairs of label and control images are
averaged together to obtain the required signal-to-noise ratio.
Technical Requirements
Performed in MRI scanners, ASL requires that the subject can
be placed in a magnetic field, and hence patients are subject
to MRI contraindications. Because ASL is a subtraction
technique, it is very sensitive to subject movement. Recently,
background suppression techniques have been proposed in
which the static tissue signal is reduced as far as possible. In
these approaches, the sensitivity of the technique to motion is
greatly reduced.112,113
Interpretation
For pulsed and continuous technique types, a control acqui-
sition is necessary. The control acquisition has to yield the
same tissue signal but without inverting the blood magneti-
zation. A simple subtraction between the averaged control
and label images yields a flow-weighted map. Various
models have been proposed to convert this flow-weighted
image into a quantitative perfusion map. The data processing
can be performed within a few minutes.103,114–116
The quantitative accuracy of the ASL technique has been
addressed extensively in the literature. Computer simulations
using an extensive model117 and direct comparisons with
other, non-nuclear MR, methods have been per-
formed.115,116,118,119 It appears that blood flow is correctly
estimated in the gray matter. In white matter, numerical
simulations predict an overestimation, whereas direct mea-
surements show an underestimation. Quantitative ASL per-
fusion maps show a10% change when rescanning the same
subject.120
The difference in signal between the label and control
acquisitions is 1% of the control images. Therefore, perfu-
sion monitoring using ASL requires a very high signal-to-
noise ratio. Because the signal difference is low, ASL cannot
accurately map blood flow below 10 mL/100 g per minute.
On the other hand, as flow increases (150 mL/100 g per
minute), ASL will underestimate blood flow. This is attrib-
utable in part to the fact that the labeled blood leaves the
voxel (reduced extraction fraction) because this can be
observed in animal models.121
In ASL techniques, the MRI sequences include spoiler
gradients that suppress the signal arising from large vessels.
Hence, ASL is not sensitive to large arteries or veins. The
signal obtained with ASL comes mainly from water located
in small vessels and in the surrounding tissue because of the
water exchange between blood and tissue.122
In case of cerebrovascular disease, in which the time for
blood to travel from the labeling plane to the imaged plane is
longer and may be spatially heterogeneous, special methods
involving long postlabeling delay times123 or acquisition of
images at multiple inversion times have to be implement-
ed.121 Even so, in the case of very long arrival times (eg, when
flow is provided by collateral networks), the magnetic label
of the blood may essentially be completely relaxed, such that
no information about perfusion can be reliably ascertained.124
Feasibility
ASL examinations can be performed on any patient that can
tolerate MRI. It is of particular interest for imaging CBF in
infants and children, given the lack of ionizing radiation or
need for intravenous access.
Perfusion maps obtained with ASL can cover the entire
brain. In humans, the typical voxel size is 224 mm or
448 mm. Because fast imaging techniques are generally
used, it can be challenging to obtain a good image quality in
regions with strong magnetic susceptibility gradients (ie,
magnetic field distortions), such as the base of the brain near
the frontal sinuses.
Successive ASL CBF maps can be acquired every other 5
to 8 seconds. Thus, ASL techniques can be used successfully
for functional MRI applications, in which control and label
images are alternatively acquired.125–127
Clinical Applications
Although ASL techniques have not entered widespread clin-
ical usage, their utility has been demonstrated for a variety of
acute and chronic cerebrovascular diseases. ASL is feasible
for acute stroke patients and other emergency patients in
hospitals with MRI access, assuming that they are stable
enough to undergo an MRI examination.
Initial studies were performed in the setting of ischemic
cerebrovascular disease (stroke and transient ischemic at-
tack), which demonstrated the feasibility of acquiring CBF
maps using ASL in the acute and chronic settings.128,129
Continuous ASL measurement of CBF reduction in the
symptomatic hemisphere were shown to have high correla-
tion with National Institutes of Health Stroke score.130 ASL
has also been used to study temporal lobe epilepsy129 and
brain tumor perfusion. A study of malignant gliomas demon-
strated ASL perfusion imaging to be equally effective in
determining tumor grade compared with DSC.131
One significant advantage of ASL is the ability to perform
multiple repeated measurements, which might be necessary
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before and after a cerebrovascular dilator (such as acetazol-
amide;132 Figure 7) or before and after a neurointerventional
procedure (such as carotid endarterectomy133 or stenting).
ASL methods also afford evaluation of functional brain
activation,134 useful, for instance, for the planning of neuro-
surgical procedures.
Doppler Ultrasound for Blood Flow Volume
Measurement in ICAs
Jean-Franc¸ois Soustiel, MD;
Thomas C. Glenn, MD
Technical Description
Numerous studies have shown the potential benefit of Dopp-
ler ultrasound–related techniques for the investigation of
cerebral hemodynamics. Although different in nature from
other imaging techniques described hereby and accordingly
limited for spatial resolution, Doppler ultrasound offers the
advantage of being noninvasive and can be repeated as often
as clinically indicated at the patient’s bedside. It does not
involve radiation, does not require any contrast medium, and
is free of any known adverse effect. In this regard, ultrasound
Doppler technology may represent a convenient tool for the
measurement of blood flow volume (BFV) in the ICA as a
correlate for CBF in the corresponding hemisphere. Optimal
BFV measurements of both ICAs are typically achieved
within 10 to 20 minutes.135,136
Technical Requirements
This technique, although implemented in most commercial
Duplex machines since the early 1990s,135,136 has not initially
gained wide acceptance because of significant inaccuracy
inherent to errors caused by the impact of angle dependency
on flow velocity and that of pulsatility on vessel diameter.137–
139 More recently, improvement in BFV measurement accu-
racy was achieved by combination of digital Doppler ultra-
sound and angle-independent dual-beam flow technology.
This combination proved to be useful to overcome technical
shortcomings of Doppler, such as angle dependency and
time-dependent variations in velocity profile and vascular
diameter.140–143 These requirements are achieved, for in-
stance, with the Quantix-ND system (Cardiosonix-
Neoprobe), which uses pulse-wave digital Doppler to inte-
grate with high-resolution temporal and spatial variations
commonly overlooked by duplex imaging.141,143
Interpretation
Angle-independent dual-beam flow is based on the simulta-
neous use of 2 ultrasound beams with a known geometrical
configuration. Using dedicated digital Doppler technology,
hundreds of sample volumes of 200 m in length at
successive depths are simultaneously sampled along each
ultrasound beam. Full fast Fourier transform analysis for each
sample volume and application of an original algorithm allow
real-time detection of flow velocity in the set of successive
gates, followed by the determination of the chord segments
that each beam traverses within the blood vessel. Because the
angle between the 2 beams is known, the insonation angles of
the 2 beams can be drawn from simple calculation based on
trigonometric and Doppler considerations.143 Further process-
Figure 7. Preacetazolamide and postac-
etazolamide ASL CBF images of a
9-year-old girl with vasculitis, high-grade
right-proximal ICA stenosis, and multiple
subacute strokes (arrow). Significant CBF
decrease is noted in the entire right
hemisphere after acetazolamide, indica-
tive of cerebrovascular steal. The effect
is particularly marked in the regions of
the subacute strokes.
Figure 8. Graphic user interface of a
computer system after a typical ICA BFV
measurement. Along with flow data,
spectra of both channels (spectrum A
and spectrum B) with corresponding flow
velocities (Flow) and diameters (Da and
Db) are displayed to assess during the
test and thereafter the adequate align-
ment of the ultrasound beam along the
vessel axis, which represents a critical
condition for accurate measurements.
Note the optimal matching of velocities
and diameters in this case. HR indicates
heart rate; Ang, angle.
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ing of the large number of small sample volumes allows
determination of the pulsatile velocity profile and vascular
diameter. Determination of the insonation angles allows
calculation of absolute blood flow velocities so that BFV can
be directly obtained through integration of the velocity profile
across the vascular cross-sectional area. BFV levels can be
calculated online and displayed on a monitor (Figure 8)
without any data postprocessing needed.
BFV measurements in the ICA may be used for the
assessment of hemispheric or global CBF. Indeed, it shows
a close and linear correlation with CBF in the correspond-
ing hemisphere measured with 133Xe clearance tech-
nique.144,145 Admittedly, hemispheric CBF is not actually
measured but estimated by BFV in the corresponding ICA
based on the correlation between both parameters. Because
this correlation is based on ICA BFV measurements,
averaged CBF should not be confused with global blood
flow because BFV in the vertebrobasilar system is not
taken into consideration.
Attention should be paid, as for any Doppler-based tech-
nique, to minimize user-related variations and errors. Accord-
ingly, examination review should take into consideration the
quality of the obtained signal and discard any recorded data
compromised by artifacts. In particular, insonation angle
should be kept between 55° and 65° induced. Further,
discrepancies between the 2 channel measurements of diam-
eter should be kept at 0.5 mm for ICA diameter and at 20%
for ICA flow velocities. Under these conditions, reproduc-
TABLE 2. Main Strengths and Weaknesses of the Imaging Techniques Dedicated to Brain Hemodynamics
Brain Perfusion Imaging Techniques
PET SPECT XeCT PCT DSC ASL Doppler
Main strengths Accurate
quantitative
measurements
Technetium
generator widely
available
Accurate
quantitative
measurements
Wide availability
of necessary
equipment,
including in the
emergency
setting
Can be combined
with fine
anatomic
imaging, DWI,
MRA,
spectroscopy,
providing the
most
comprehensive
information in
one examination
Repeatability
(attributable to a
lack of ionizing
radiation)
Can be performed
at bedside
Assessment of
multiple factors
using various
radioligands
Can be used at
bedside and in
the emergency
setting
Assessment of
multiple brain
levels
Access to
multiple perfusion
parameters (CBV,
CBF, MTT)
Repeatability
(attributable to a
lack of ionizing
radiation)
Noninvasiveness
(no intravenous
injections)
Repeatability
(attributable to a
lack of ionizing
radiation)
Repeated
measurements
possibly
attributable to
short half-life of
radiotracers
Low cost Can be repeated
at 10-minute
intervals providing
an ability to
measure the CBF
response to
interventions
Accurate
quantitative
measurements
Whole brain
coverage
flexibility (spatial
resolution and
imaging time can
be traded off
depending on the
clinical question)
Noninvasiveness
(no intravenous
injections)
Main
weaknesses
Impossible to use
in the emergency
settings
Relative, not
quantitative
measurements
Relatively long
acquisition time,
prone to motion
artifacts
Presently limited
anatomic
coverage
Lack of
standardization in
the interpretation
CBF
underestimation
associated with
extremely delayed
arterial arrival
times (such as
through collateral
pathways)
Provides only one
value for each
brain hemisphere
High cost
(however,
cost-effective in
well-established
diagnostic
algorithms)
Poor spatial
resolution
Inhalation of
Xenon via a face
mask
use of ionizing
radiation and
iodinated contrast
media
Not available in
the emergency
settings in most
institutions
Relatively low
signal-to-noise
ratio per unit time
Operator
dependent
Xenon not
currently
approved by the
FDA (technology
only available at
this time under
IND status)
Difficulties
associated with
obtaining MRI
(claustrophobia,
contraindications,
and access
issues)
Difficulties
associated with
obtaining MRI
(claustrophobia,
contraindications,
and access
issues)
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ibility of the measurements has proved to be satisfactorily
low with interobserver variations ranging from 2.7% to 5.2%.
Feasibility
Doppler ultrasound is noninvasive and can be easily per-
formed at patients’ bedside for adults and children. Exami-
nations can be obtained repeatedly or even set to a monitoring
mode that may be critical in clinical situations characterized
by dynamic changes. Yet improvement of temporal resolution
is balanced by limited spatial resolution because BFV mea-
surements performed on each ICA are related to hemispheric
CBF, allowing only side-to-side difference analysis. Accord-
ingly, focal CBF impairments confined to a rather small area
or secondary to single vessel pathology may be masked by a
remaining and otherwise preserved hemispheric flow.143
Clinical Applications
BFV measurements in the ICA represent a convenient tool for
a bedside evaluation of hemispheric and global CBF. The
high flexibility of this technique allows the operator to fit
without interference within the busy environment of an
intensive care unit or emergency room and obtain real-time
data on CBF dynamics of unstable patients.
BFV measurements in the ICA may represent a potentially
useful tool for the investigation of vasomotor response as part
of the evaluation of cerebral occlusive disease and stroke
instead of less accurate transcranial Doppler.141 BFV mea-
surements of extracranial vessels may be of benefit to provide
additional objective information about the cerebral hemody-
namic effects of ICA occlusion.146–148 BFV measurements
are also useful to detect CBF impairment attributable to either
increased intracranial pressure or vasospasm after traumatic
brain injuries and subarachnoid hemorrhage, respectively.144
In these critically ill patients, clinical changes may develop
rapidly and therefore be overlooked by sparsely performed
CBF imaging studies. Further evaluations of drugs influenc-
ing CBF such as anesthetics, mannitol, and antihypertensive
agents or any therapeutic measure may be of utmost impor-
tance for decision making, implying repeated CBF measure-
ments within a short time. BFV measurements in the ICA
adequately fulfill all these requirements.
Conclusion
Imaging techniques dedicated to brain perfusion all address
the same types of pathological conditions, each having its
own advantages and drawbacks (Table 2). PET is quantita-
tively accurate but feasible only in very specific settings. Its
main application at the present time is its use for selection of
patients with chronic ICA occlusion for bypass surgery.
XeCT, on the other hand, is a reproducible quantitative
technique that can be more easily used in the current clinical
settings. It has classically been used for challenges such as
acetazolamide. The main limitation of XeCT is that Xenon is
not currently approved by the FDA and is available at this
time only under IND status. Doppler ultrasound is the easiest
technique to perform at bedside and is consequently used in
numerous institutions as the primary tool to assess brain
hemodynamics. Its main drawback lies in the fact that it does
not provide values for each brain region (but only 1 value for
each supplying vessel or each hemisphere). To a certain
extent, SPECT can also be performed at bedside: the radio-
pharmaceutical can be administered at the moment of the
acute event, typically the seizure, and imaging is performed
later, after stabilization of the patient, to identify the active
epileptic focus. Among SPECT tracers, 133Xe is not only
historically the most important method for measuring brain
hemodynamics but is still used as a gold standard in many
hospitals that do not have PET. Doppler ultrasound and ASL
do not use any contrast medium and do not require radiation.
They can be used repeatedly and, hence, are useful for
intensive care monitoring (for Doppler ultrasound that can be
performed at bedside) or functional imaging (for ASL). PCT
technique can be performed on conventional CT scanners
and, as such, represents an ideal technique for ED patients,
including stroke patients and head trauma patients. Finally,
DSC can be combined with other MRI sequences, such as
fine anatomic imaging, DWI, spectroscopy, etc, to provide
the most comprehensive information in one examination and
leading to a high benefit/cost ratio.
In conclusion, all imaging techniques dedicated to brain
hemodynamics have their own advantages in specific clinical
settings. The selection of one over another technique depends
on the intrinsic characteristics pertaining to each imaging
technique but also on the settings and on the knowledge and
experience of institution staff.
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